A-Synaptic Canada Inc., A-Synaptic’s first prescription product is the transdermal delivery of cannabidiol for the treatment of childhood epilepsy. There is a predicate product in the United States, Epidiolex, which orally delivers CBD for the treatment of childhood epilepsy. This means that A-Synaptic is able to use the streamlined 505(b)(2) regulatory pathway to approval.
In addition to epilepsy, other potential treatments include:
peripheral muscular skeletal pain (osteoarthritis)
ulcers (including diabetic foot ulcers and bed sores)